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Abstract
Background: Hepatic failure has been associated with reported therapeutic use of acetaminophen
by alcoholic patients. The highest risk period for alcoholic patients is immediately after
discontinuation of alcohol intake. This period exhibits the largest increase in CYP2E1 induction and
lowest glutathione levels. Our hypothesis was that common liver tests would be unaffected by
administration of the maximum recommended daily dosage of acetaminophen for 3 consecutive
days to newly-abstinent alcoholic subjects.
Methods: Adult alcoholic subjects entering two alcohol detoxification centers were enrolled in a
prospective double-blind, randomized, placebo-controlled trial. Subjects were randomized to
acetaminophen, 4 g/day, or placebo for 3 consecutive days. The study had 95% probability of
detecting a 15 IU/L difference in serum ALT.
Results: A total of 443 subjects were enrolled: 308 (258 completed) received acetaminophen and
135 subjects (114 completed) received placebo. Study groups did not differ in demographics,
alcohol consumption, nutritional status or baseline laboratory assessments. The peak mean ALT
activity was 57 ± 45 IU/L and 55 ± 48 IU/L in the acetaminophen and placebo groups, respectively.
Subgroup analyses for subjects presenting with an elevated ALT, subjects fulfilling a diagnosis of
alcoholic hepatitis and subjects attaining a peak ALT greater than 200 IU/L showed no statistical
difference between the acetaminophen and control groups. The one participant developing an
increased international normalized ratio was in the placebo group.
Conclusion:  Alcoholic patients treated with the maximum recommended daily dose of
acetaminophen for 3 consecutive days did not develop increases in serum transaminase or other
measures of liver injury. Treatment of pain or fever for 3 days with acetaminophen appears safe in
newly-abstinent alcoholic patients, such as those presenting for acute medical care.
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Background
Acetaminophen (paracetamol) is a safe and effective over-
the-counter (OTC) analgesic and antipyretic that has been
used clinically for over 50 years. It is widely considered an
appropriate first-line treatment for patients with fever, as
well as for a variety of conditions causing mild to moder-
ate pain.
Acetaminophen is used by over 50 million adults in the
United States each week [1]. Reports of hepatic failure and
death following the intended therapeutic use of acetami-
nophen by patients who consume alcohol have been pub-
lished. Some practitioners recommend that the maximum
dose of acetaminophen be lowered from the current dose
of 4 g/day or that acetaminophen be avoided completely
in alcoholic patients. As acetaminophen is used without
injury by a large number of people with a history of alco-
hol ingestion, the apparent overall risk appears low. A sys-
tematic review of acetaminophen use in alcoholic subjects
concluded that there was little credible evidence implicat-
ing therapeutic doses of acetaminophen as a cause for ful-
minant hepatotoxicity in alcoholics [2]. Nevertheless, the
United States Food and Drug Administration (FDA)
requires that the labels of non-prescription analgesic
drugs, including acetaminophen products, warn patients
who consume more than three alcoholic drinks daily to
discuss the use of acetaminophen with their doctor.
The principal determinant of acetaminophen-induced
liver injury is believed to be the reactive metabolite, N-
acetyl-p-benzoquinoneimine (NAPQI), produced prima-
rily by CYP2E1-mediated oxidation of acetaminophen.
The primary defense against the toxic actions of this
metabolite is the hepatic store of reduced glutathione
(GSH). Plasma GSH concentrations are thought to pro-
vide a reasonable surrogate assessment of hepatic GSH
stores [3]. Published data suggest that that the plasma
GSH concentration is decreased in alcoholic subjects [4],
particularly in those ingesting acetaminophen [5].
Previous research has shown that a 2-day course of aceta-
minophen in subjects with chronic alcoholism did not
cause changes in aspartate aminotransferase (AST),
alanine aminotransferase (ALT), bilirubin or interna-
tional normalized ratio (INR). It has been proposed that
the 2-day course of treatment was of insufficient duration
to induce hepatic injury [6-9]. The purpose of this study
was twofold: (1) to determine if a 3-day course of aceta-
minophen dose (4.0 g/day) affects the serum ALT, AST or
INR, and (2) to determine if the plasma concentration of
reduced glutathione is affected by this acetaminophen
dosing regimen.
Methods
A randomized double-blind placebo-controlled trial of
alcoholic subjects 18 years or older, admitted to the Den-
ver Health Comprehensive Addictions Rehabilitation and
Evaluation Services (CARES) in Denver, CO, USA or
Recovery Centers of King County (RCKC) in Seattle, WA,
USA from January 2002 through July 2004 was con-
ducted. The study consisted of 3 consecutive days of study
drug dosing followed by 2 days of observation with con-
tinuous monitoring for the 5-day period.
Participants were eligible for enrollment if they had a
detectable breath ethanol concentration at admission to
the detoxification facility. Exclusion criteria included a
baseline serum AST or ALT above 200 IU/L, baseline INR
above 1.5, baseline serum acetaminophen concentration
above 20 mcg/mL, a history of ingesting more than 4 g/
day of acetaminophen for any of the 4 days preceding
enrollment, a history of allergy to acetaminophen, enroll-
ment in any other trial within the preceding 3 months, or
a positive serum pregnancy test.
A structured history and physical was used to assess med-
ication and alcohol use as well as nutritional status. For-
mal screening for alcoholism included the CAGE
questionnaire and the Brief Michigan Alcoholism Screen-
ing Test (MAST) [10-13]. Nonprescription and prescrip-
tion medication use was documented with specific
questioning about ingestion of substances that bind to,
induce or inhibit CYP2E1 (e.g. isoniazid, chlorzoxazone,
disulfiram). Study investigators clinically classified each
participant into one of the following categories: normal
nutritional status, mild malnutrition, or severe malnutri-
tion [14]. Body mass index (BMI kg/m2) was calculated.
The study was approved by the institutional review boards
governing the institutions involved, namely the Colorado
Multiple Institutional Review Board (COMIRB) for
CARES and the Western Institutional Review Board
(WIRB) for RCKC. Written informed consent was
obtained from all subjects after they were documented to
have nondetectable breath ethanol levels. Each subject
received $10.00 per day.
Assignment
Each eligible participant was randomized to receive either
acetaminophen or placebo at a 2:1 ratio. An investigator
not involved with participant management generated the
randomization codes for each site using statistical soft-
ware (StatMate version 1.011; GraphPad Software Inc, San
Diego, CA, USA). Group assignments were blinded for
participants, staff and investigators.
Masking
Acetaminophen was purchased from a retail store (Extra
Strength Tylenol® tablets, 500 mg per caplet; McNeil Con-
sumer and Specialty Pharmaceuticals, Fort Washington,BMC Medicine 2007, 5:13 http://www.biomedcentral.com/1741-7015/5/13
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PA, USA). Placebo capsules contained granulated sugar.
To maintain blinding, placebo and acetaminophen doses
were placed in identical pill casings and stored in
uniquely coded individual bags by study personnel not
involved in evaluation or management of subjects.
Participant flow and follow up
Baseline blood specimens were drawn in the morning
prior to administration of study medication and each
morning of study days 2 through 5 in order to avoid the
effects of diurnal variation. Baseline testing included
serum acetaminophen level, complete blood cell count
(CBC), serum electrolytes with renal function tests,
hepatic panel (AST, ALT, and bilirubin), INR, γ-glutamyl
transferase (GGT) and, in female subjects, serum β-
human chorionic gonadotropin (β-HCG). Hepatic panel
and INR testing were performed on days 2 to 4 of the
study. Serum acetaminophen level was repeated on day 3.
Laboratory testing on day 5 was similar to baseline with-
out GGT testing. Specimens from CARES were assayed in
the clinical laboratory of Denver Health Medical Center
(Denver, CO, USA). Specimens from RCKC were assayed
at Dynacare Laboratories or Quest Diagnostics (Seattle,
WA, USA). Breath ethanol levels were determined at ini-
tial presentation to the treatment center, usually in the
evening or early morning before enrollment and prior to
the first administration of study medication. Measure-
ment of plasma GSH at baseline and again on study day 3
was completed in a subset of consecutive participants at
CARES. This assay was performed at The Clinical Pharma-
cokinetic Laboratory of the Fred Hutchinson Cancer
Research Center in Seattle, WA. A sample handling proto-
col was used in obtaining and processing these samples to
limit pre-analytical variability.
Subjects who left the detoxification center during the
study were withdrawn from the trial. Study medications,
2 × 500 mg acetaminophen capsules or 2 × placebo cap-
sules, were dispensed by nursing staff or study investiga-
tors who directly verified and recorded the time of
ingestion. At CARES, the dosing schedule was 09:00,
13:00, 17:00 and 23:00. At RCKC, the dosing schedule
was 08:30, 12:30, 16:30 and 20:30 for the first eight par-
ticipants and then 08:00, 12:00, 16:00, and 20:00 for the
remaining participants.
The study physician was notified of any subject who
developed an ALT or AST level > 200 IU/L. The blind was
broken for these subjects to assist the study physician in
making treatment decisions. A total of 10 participants (8
acetaminophen, 2 placebo) were unblinded in this man-
ner. No participant suffered acetaminophen-related liver
injury.
Analysis
The primary outcome of interest was a change in the
serum ALT activity or the INR. Secondary outcomes were
the serum bilirubin and the plasma glutathione concen-
trations. Demographic and clinical laboratory data for all
subjects in the two study groups were compared using a
statistical software package (SPSS Inc, Chicago IL, USA).
Chi-Square or exact tests were used to compare categorical
data such as gender and ethnicity, while an unpaired Stu-
dent t test or analysis of variance (ANOVA) was used to
compare continuous numerical data such as age and most
laboratory findings. Repeated measures analysis of vari-
ance (ANOVA) was used to compare continuous numeri-
cal data (i.e. ALT, AST) within groups from greater than
three time points. In all analyses, a two-sided p value <
0.05 was considered significant.
Results
Of the 509 subjects screened for eligibility, 66 were
excluded prior to receiving study medication (Figure 1).
Of these 66 excluded subjects, 24 were due to baseline
serum AST or ALT > 200 IU/L, 16 presented to the facility
with nondetectable breath ethanol, 15 requested to be
withdrawn, 1 had a baseline INR greater than 1.5, 2 were
removed due to protocol violations, and 8 because the
nursing staff determined that the facility could not accom-
modate these subjects, usually for behavioral reasons.
The remaining 443 participants were randomized: 308
subjects were assigned to receive acetaminophen and 135
subjects were assigned to receive placebo. After randomi-
zation, 50 subjects withdrew from the acetaminophen
group and 21 from the placebo group (Figure 1). Five par-
ticipants withdrew due to adverse events unrelated to the
study medication: 2 in the acetaminophen group (both
from alcohol withdrawal symptoms) and 3 in the placebo
group (1 from frostbite, 1 from alcohol withdrawal symp-
toms, 1 from abdominal pain). The remaining subjects
Disposition of participants Figure 1
Disposition of participants.
ENROLLED=509
EXCLUDED=66
Patient requested withdrawal from study=15
Did not meet inclusion/exclusion criteria=41
Protocol Violation=2
Withdrawn by site staff or study personnel=8
RANDOMIZED=443
ACETAMINOPHEN
GROUP=308
PLACEBO
GROUP=135
WITHDRAWN=50
Patient requested withdrawal=48
Unrelated Adverse Event=2
WITHDRAWN=21
Patient requested
withdrawal=18
Unrelated Adverse Event=3
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(48 in the acetaminophen group, 18 in the placebo
group) withdrew from the study because they did not
want to remain in the treatment facility. Withdrawal rates
were 16% for both the acetaminophen and placebo
groups (p > 0.05).
Study groups were of similar demographic and baseline
characteristics, including baseline serum AST, ALT, INR,
and bilirubin (Table 1). Minority ethnic groups were well
represented. More than 80% of study participants
reported their most recent drinking episode lasting more
than 1 week (Table 1).
Analyses of ALT and AST were highly concordant, so only
ALT results are shown. The mean baseline serum ALT of
the acetaminophen group was 49 ± 38 IU/L and 47 ± 37
IU/L in the placebo group. Both the acetaminophen and
placebo groups experienced statistically significant varia-
tion in the serum ALT during their course; however, there
was no difference between the two groups at any point
(Table 2). For both groups, the highest mean ALT
occurred on day 5. The study had 95% probability of
detecting a mean difference in the serum ALT of 15 IU/L.
There was no significant change in mean INR, total
bilirubin, or any other laboratory analysis between the
study groups throughout the study (p > 0.05).
A series of post-hoc analyses were performed to explore
the possibility that a subgroup of participants could have
had a different response to acetaminophen administra-
tion (i.e. that a susceptible subpopulation exists). None of
the analyses indicated a statistical difference between the
acetaminophen and placebo groups, although some anal-
yses had few subjects and limited power to detect a differ-
ence. The ALT stayed the same or decreased from baseline
in 31% of subjects in the placebo group and 36% of sub-
jects in the acetaminophen group. The ALT increased
above baseline in 66% of participants with a maximum
increase of 1–254 IU/L in the acetaminophen group and
1–158 IU/L in the placebo group. A total of 32 partici-
pants (24 acetaminophen, 8 placebo) developed an ALT
greater than three times the upper limit of normal (ULN)
at some point during the course of the study (Figure 2). A
total of 11 subjects developed an ALT greater than 200 IU/
L at some time during the study (9 acetaminophen, 2 pla-
cebo). The maximum ALT and AST measures were 312
and 448 IU/L, respectively. One subject developed coagu-
lopathy; this subject was in the placebo group and had an
INR of 1.8 on day 3. A bilirubin that exceeded the upper
limit of normal at any time was found in 20 (6.4%) in the
acetaminophen group and 6 (4.4%) in the placebo group.
There were 156 participants (106 acetaminophen, 50 pla-
cebo) that entered the study with a serum ALT above the
ULN. The ALT group means of those with a baseline ALT
Table 1: Baseline characteristics of patients in acetaminophen 
and placebo groups
Acetaminophen 
group (n = 308)
Placebo group 
(n = 135)
p-
value*
Age:
Mean ± SD 43 ± 9 44 ± 8 0.399
Range 18–72 20–65
Male (%) 284 (92) 128 (95) 0.322
Ethnic Origin (%):
Caucasian 156 (51) 68 (50) 0.830
Hispanic 45 (15) 22 (16)
African Descent 49 (16) 16 (12)
Native American 43 (14) 23 (17)
Other 15 (5) 6 (4)
Body Mass Index:
Mean ± SD 25 ± 5 25 ± 4
Range 15–55 17–39
Breath alcohol level at 
presentation to 
detoxification site:
0.711
Mean ± SD 0.161 ± 0.093 0.157 ± 0.099
Range 0.001–0.710 0.001–0.550
Self-reported alcoholic 
(%)
301 (98) 133 (99) 0.729
Duration of most recent 
drinking binge:
< 1 week 56 (18) 22 (16) 0.193
1–4 weeks 98 (32) 36 (27)
> 1 month 154 (50) 76 (56)
Not reported 0 (0) 1 (1)
CAGE (no. of yes 
answers; mean ± SD)
3.3 ± 0.9 3.3 ± 0.9 0.645
Alanine aminotransferase:
mg/dL 49 ± 38 47 ± 37 0.398
Range 4–189 8–175
Aspartate 
aminotransferase:
IU/L 55 ± 39 55 ± 38 0.650
Range 6–198 12–194
International normalized 
ratio:
0.652
INR 0.96 ± 0.09 0.96 ± 0.09
Range 0.79–1.40 0.80–1.30
Albumin: 0.589
g/dl 3.94 ± 0.45 3.93 ± 0.37
Range 2.1–4.8 2.8–4.0
Total bilirubin:
mg/dL 0.74 ± 0.53 0.68 ± 0.45 0.286
Range 0.1–4.1 0.1–2.8
Gamma glutamyl 
transferase:
IU/L 161 ± 308 168 ± 274 0.799
Range 9.0–3492 12.0–1893
*Standardized values based upon upper limit of normal were used 
to calculate p-values.
Normal ranges for Denver and Seattle sites are as follows. Alanine 
aminotransferase: Denver, ALT 5–40 mg/dL male, 5–36 mg/dL 
female; Seattle, 0–50 IU/L and 2–60 IU/L male, 2–40 IU/L female. 
Aspartate aminotransferases: Denver, 9–36 IU/L; Seattle: 0–50 IU/L 
and 2–50 IU/L male, 2–35 IU/L female (both). International 
normalized ratio: Denver, 0.82–1.17; Seattle, 0.9–1.1. Total 
bilirubin: Denver, 0.2–1.2 mg/dL; Seattle: 0.1–1.2 mg/dL and 0.2–1.5 
mg/dL male, 0.2–1.3 mg/dl female. Gamma glutamyl transferase: 
Denver, 6–50 IU/L; Seattle: 5–105 IU/L male, 2–98 IU/L female and 
2–80 IU/L male, 2–60 IU/L female. Albumin: Denver, 3.4–5.5 g/dl; 
Seattle, 3.3–5.0 and 3.5–4.9 g/dlBMC Medicine 2007, 5:13 http://www.biomedcentral.com/1741-7015/5/13
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greater than the ULN were consistently two to three times
higher throughout the trial, regardless of group assign-
ment (Figure 3).
To assess the effect of acetaminophen administration on
participants fulfilling a case definition of alcoholic liver
disease, a post-hoc analysis was performed using the 44
subjects in whom the baseline AST/ALT ratio was 2.0 or
greater [15]. The mean ALT of the group without evidence
of alcoholic liver disease was significantly higher through-
out the trial than the group with evidence of alcoholic
liver disease; however, the acetaminophen and placebo
groups were not statistically different (Figure 4). The peak
ALT measure of these 44 subjects was 75 IU/L compared
to 312 IU/L for the entire study sample. No subject with
an AST to ALT ratio of 2.0 or greater developed an ALT
more than three times the ULN or reported any study-
related adverse events.
Plasma reduced glutathione concentration was deter-
mined at baseline and on day 3 in a subset of 79 consecu-
tive participants (56 acetaminophen, 23 placebo). Plasma
glutathione increased from 2.17 ± 0.97 to 2.27 ± 0.85 µM
in the acetaminophen group and from 1.90 ± 0.68 to 2.02
± 0.74 µM in the placebo group. There was no difference
between treatment or placebo groups (p > 0.05). The cor-
relation between plasma GSH concentration and ALT, AST
or INR was not significant (p > 0.05).
The role of nutritional status was explored. Neither body
mass index nor any degree of malnutrition correlated with
increases in ALT. There were eight serious adverse events
experienced by five patients: one infection with methicil-
lin resistant staphylococcus, one abdominal pain, three
patients who developed delirium tremens, two patients
developed confusion and one patient developed ataxia.
These events were deemed serious because they resulted in
hospitalization of the patient. One event was possibly
Serum alanine aminotransferase (ALT) stratified by baseline  ALT value Figure 3
Serum alanine aminotransferase (ALT) stratified by baseline 
ALT value.
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Table 2: Serum alanine aminotransferase (ALT) measures 
(intent to treat analysis)
Serum ALT (IU/L)
Acetaminophen group Placebo Group p-value*
Day 0:
Mean ± SD 49 ± 38 47 ± 37 0.398
Range 4–189 8–175
n3 0 8 1 3 5
Day 2:
Mean ± SD 45 ± 38 46 ± 34 0.949
Range 7–292 6–174
n2 8 7 1 2 4
Day 3:
Mean ± SD 45 ± 36 50 ± 38 0.245
Range 7–230 6–242
n2 7 4 1 1 8
Day 4:
Mean ± SD 48 ± 39 52 ± 43 0.411
Range 6–264 8–288
n2 6 7 1 1 5
Day 5:
Mean ± SD 57 ± 45 55 ± 48 0.706
Range 7–312 7–282
n2 6 1 1 1 4
*Standardized values based upon upper limit of normal were used to 
calculate p-values.
Normal ranges for CARES: ALT 5–40 IU/L male and 5–36 IU/L female. 
Two different labs were used by RCKC, normal ranges: ALT 0–50 IU/
L and 2–60 IU/L male, 2–40 IU/L female.
Incidence of alanine aminotransferase (ALT) measures  greater than three times upper limit of normal throughout  study by treatment group Figure 2
Incidence of alanine aminotransferase (ALT) measures 
greater than three times upper limit of normal throughout 
study by treatment group.
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related to the study medication. This patient experienced
abdominal pain after receiving three doses of placebo.
Discussion
The administration of acetaminophen 4 g/day for 3 con-
secutive days to newly-abstinent chronic alcoholic sub-
jects did not result in a change in serum ALT, AST,
bilirubin, or INR. Our study had 95% power to detect a 15
IU/L change in AST or ALT, a smaller change than is typi-
cally used by common definitions of liver injury [16].
This study was designed to safely maximize the opportu-
nity to detect a potential alcohol-acetaminophen interac-
tion. Participants had been drinking alcohol for a
prolonged period and abruptly discontinued alcohol
intake upon presentation to the detoxification facility.
This presentation reproduces the conditions commonly
cited in reports of acetaminophen injury associated with
therapeutic doses in the medical literature: namely, induc-
tion of CYP2E1 and concomitant depletion of glutathione
[17-20].
Hepatic injury from acetaminophen is caused by the pro-
duction of a reactive metabolite N-acetyl-p-benzoquinon-
eimine (NAPQI). Only a small percentage of
acetaminophen is converted by CYP2E1 to NAPQI, which
is normally detoxified by hepatic glutathione (GSH). If
GSH stores are depleted, NAPQI can bind to hepatocellu-
lar components resulting in liver injury. Conditions
which can increase NAPQI production, such as induction
of CYP2E1 by alcohol, or conditions that decrease GSH
stores, such as malnutrition, are postulated to increase the
risk of acetaminophen-induced hepatic injury [5,17,19-
24]. Human studies have demonstrated that chronic alco-
hol exposure can increase CYP2E1 activity, up to approxi-
mately twice baseline [12]. Increased CYP2E1 activity
begins immediately upon exposure to ethanol [21]. Fol-
lowing cessation of chronic alcohol exposure, human
studies have also demonstrated that CYP2E1 induction is
transient, lasting at most a few days [25]. Animal and
human data suggest that different mechanisms can con-
tribute, to different degrees and at different ethanol con-
centrations, to increasing CYP2E1 activity [8,9,26,27].
The alcohol-induced induction of CYP2E1 wanes follow-
ing alcohol abstinence with a half-life of approximately
2.5 days and CYP2E1 activity reaching normal in 3 to 8
days [12,25,28]. Our subjects were treated with acetami-
nophen in a period of probable CYP2E1 induction and
potentially reduced plasma glutathione concentration,
recreating the conditions postulated to allow liver injury
in acetaminophen-treated patients who ingest alcohol.
As it is possible that subjects who did not develop
transaminase abnormalities secondary to acetaminophen
could obscure a potential detrimental effect in a small
sub-group, several post-hoc analyses were performed in
an attempt to identify trends that would guide further
study of alcoholic patients. The analyses included the sub-
group of participants that presented with an initially ele-
vated ALT or AST, participants meeting a common
definition of alcoholic hepatitis, the relationship of body
mass index to change of ALT and several others. These
analyses are limited by the reduction in statistical power
created by the reduced number of subjects present in a
subgroup analysis. However, none of the analyses identi-
fied a group that responded to acetaminophen ingestion
with an increase in serum ALT or AST, bilirubin concentra-
tion or INR.
The medical literature contains few prospective studies
involving administration of acetaminophen to newly-
abstinent alcoholic patients. Lauterburg found that
plasma glutathione concentration was decreased in eight
newly-abstinent alcoholic subjects and decreased further
following a single supratherapeutic dose of acetami-
nophen (2 g) [5]. As shown by the increase in glutathione
in both experimental groups, our results suggest that the
alcoholic patient has blood concentrations of glutathione
that increase when alcohol ingestion is terminated. In
contrast to the Lauterburg study, our subjects group
receiving acetaminophen 1 g four times daily did not
develop a decrease in the plasma concentration of glutath-
ione.
Our results differ from Watkins et al, who reported that
31% to 44% of healthy young acetaminophen treated
Serum alanine aminotransferase (ALT) in patients with alco- holic liver disease Figure 4
Serum alanine aminotransferase (ALT) in patients with alco-
holic liver disease.
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patients experienced an ALT greater than three times the
upper limit of the normal range (3 × ULN) during treat-
ment with the acetaminophen, 4 g/day for 14 days [29].
In contrast only 6% of our patients developed an ALT
greater than 3 × ULN after 3 days of treatment and the
same rate was observed in the placebo group. There are
several potential explanations for this difference. First, the
subject groups are considerably different: young normal
subjects vs older alcoholic subjects. Alcoholic subjects
repeatedly insult their liver, which might decrease the
response to another stimulus. Second, although daily ALT
values were not provided in the Watkins manuscript, the
author stated that "Elevation of ALT to more than three
times the ULN (120 U/L) was not observed prior to day 3
in any of the treatment groups." Similarly, our results
indicate that the proportion of patients with an ALT
greater than 3 × ULN (some patients started with ALT >
ULN) decreased on day 2 and then increased slightly on
days 3, 4 and 5 (Figure 2). Although the increase in ALT
also occurred in the control group, we cannot exclude that
the serum ALT of our patients would not have followed a
course similar to those reported in Watkins. Finally, previ-
ous randomized trials established previously that the
serum aminotransferase activity increases in some
patients during treatment with acetaminophen, however,
none of those studies determined ALT as frequently
(daily) or as early in the course as Watkins [30]. The
meaning of asymptomatic increases in serum ALT is
unknown. Further research with administration for longer
periods in alcoholic patients is needed to answer these
questions.
Previous research by our group involving administration
of acetaminophen to alcoholic subjects for 2 days sup-
ports the findings of the current study [31,32]. Therapeu-
tic acetaminophen dosing in a total of 132 subjects
showed no effect on serum ALT, AST, bilirubin or INR.
Recently, Bartels et al studied the administration of aceta-
minophen for 4 days. He also found no difference in
serum glutathione S-transferase (GST), an indicator of
hepatocyte enzyme release similar to ALT and AST [13].
Although they are few, all prospective studies in alcoholic
subjects to date have failed to find liver injury associated
with therapeutic doses of acetaminophen.
There are limitations to the generalizability of our results.
We only studied the maximal recommended daily dose of
acetaminophen (4.0 g/day), so our data should not be
extrapolated to either intentional or unintentional over-
doses. Larson et al reported on patients entered into the
Acute Liver Failure registry [33]. Among patients with liver
injury thought to be acetaminophen-related, referred to a
liver service participating in the registry and fulfilling the
diagnosis of acute liver failure, 51% reported therapeutic
intent and 63% reported use of an acetaminophen-opioid
combination drug. Most patients ingested an overdosage
of acetaminophen with a mean dosage of 7.5 g/day (range
1–78 g/day). It is crucial to distinguish between ingestion
of a true therapeutic dose and ingestion of an overdose
despite therapeutic intent.
Our results do not apply to all alcoholic patients. By
including subjects with higher aminotransferase levels
than previously studied, we were able to enroll more than
95% of alcoholic volunteers screened. However, we did
not study patients with decompensated alcoholic liver dis-
ease. Our results might therefore not apply to patients
with liver disease severe enough to impair hepatic syn-
thetic function.
We evaluated a 3-day course of acetaminophen therapy.
As cytochrome induction wanes substantially in the first 2
days, an alcoholic patient would be expected to be at high-
est risk during the first day following cessation of alcohol
intake. We did not study alcoholic patients that continued
to ingest alcohol concurrently with acetaminophen. How-
ever, acute ingestion of alcohol inhibits rather than
increases NAPQI formation, so it is unlikely that acute
alcohol consumption would increase the susceptibility of
alcoholic patients to liver injury [2,21,24,34]. The metab-
olism of acetaminophen produces a protein adduct of
acetaminophen composed of a cysteine residue covalently
bound to acetaminophen. In the future, this assay could
allow quantitation of the amount of acetaminophen actu-
ally metabolized by a patient and allow stratification and
analysis of the risk of hepatotoxicity in patients receiving
acetaminophen [35,36].
Claims of a potential acetaminophen-alcohol interaction
have prompted some healthcare providers to recommend
a decreased dose or complete avoidance of acetami-
nophen for patients who drink alcohol. If patients who
drink alcohol are instructed to avoid acetaminophen alto-
gether, they will likely use other OTC analgesics such as
aspirin or other nonsteroidal anti-inflammatory medica-
tions (NSAIDs). NSAIDs and aspirin cause significant
morbidity and mortality at or near the therapeutic dosage.
Precise data are not available, but it is estimated that
100,000 Americans are hospitalized and 16,000 patients
die each year in the United States from gastrointestinal
hemorrhage, ulcers and perforations secondary to NSAIDs
and aspirin [15,20,35,37]. The FDA has recognized the
significance of this risk and since 1998 has mandated that
OTC NSAIDs such as ibuprofen and naproxen sodium
carry an alcohol warning.
The alcohol warning on all common OTC analgesics
advises people who consume three or more alcoholic
drinks every day to consult a doctor before using these
drugs. Healthcare providers are commonly faced with theBMC Medicine 2007, 5:13 http://www.biomedcentral.com/1741-7015/5/13
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question of which OTC analgesic is the safest for patients
who occasionally drink alcohol as well as for those
patients who are suspected or confirmed alcoholics. The
answer to this question requires an assessment of the risks
of each analgesic. A recent study suggested that NSAID
treatment produces a tenfold increase in risk of gastroin-
testinal bleeding for patients within 1 week of initiating
therapy [38]. Although we did not directly compare the
safety of NSAIDS to acetaminophen, we were unable to
find any evidence of liver injury in "high risk" subjects
ingesting acetaminophen. Acetaminophen is present in
many OTC products. Inadvertent concurrent use of these
products could exceed the maximum recommended dos-
age of 4 g/day. The relative susceptibility of alcoholic
patients and other patients in doses above 4 g/day is
unclear.
Conclusion
Overall, treatment of pain or fever for 3 days with aceta-
minophen appears safe in newly-abstinent alcoholic
patients, such as those presenting for acute medical care.
This study and other prospective data suggest that short-
term maximal therapeutic acetaminophen dosing does
not cause liver injury in alcoholics.
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